About acute myeloid leukaemia (AML)

Acute myeloid leukaemia (AML) is a fast-growing blood cancer. It develops when myeloid stem cells in your bone marrow divide and mature uncontrollably. Find out about the signs and symptoms of AML, tests you might have, and what to expect.

Summary

AML is a fast-growing type of blood cancer. It starts in blood-forming cells in your bone marrow called myeloid stem cells.
We do not know the exact cause of AML, but it is not because of anything you have or have not done.
The signs and symptoms of AML vary from person to person. You may:
- Feel exhausted for no reason (fatigue)
- Have infections that last a long time or keep coming back
- Feel tired, dizzy or short of breath
- Get unexpected bruising or bleeding like nosebleeds, bleeding gums, blood spots or rashes
- Have a high temperature (fever)
- Have bone pain
- Have tummy pain or fullness
AML is diagnosed based on blood tests and bone marrow tests. Depending on your symptoms you might have further tests and scans.
As with most cancers outcomes vary from person to person and depend on many different factors. Your haematology team are best placed to discuss what they expect for you because they know your individual circumstances.
We have separate information about treatment for AML.

Download our factsheet about AML

Download our booklet about AML

Order our AML booklet in print

What is AML?

AML is a fast-growing type of blood cancer. It starts in blood-forming cells in your bone marrow called myeloid stem cells.

If you have AML, these cells multiply too much. They divide and mature uncontrollably. This leads to an increase in the different types of white blood cells in your blood and bone marrow. As the leukaemia cells build up, they can fill up your bone marrow stopping it from making enough healthy red and white blood cells.

There are different subtypes of AML, which can affect what treatment you have. They are based on:

The genetic changes in your leukaemia cells
What your leukaemia cells look like under a microscope

Your haematology team should tell you what subtype of AML you have and what it means for you. Some of the more common subtypes include:

Who gets AML?

AML is one of the most common types of leukaemia. Around 2,710 people are diagnosed with it each year in the UK.

AML can affect people of any age, but it is more common in people over 65.

What causes AML?

We do not know the exact cause of AML. People with AML have genetic changes in their leukaemia cells that stop the cells from working properly. We do not know why these genetic changes occur. These changes are not because of anything you have or have not done. But some factors can increase your chance of getting AML, which include:

Your age – AML is more common in people over 65
If you have previously had chemotherapy, radiotherapy or another type of blood cancer
Exposure to certain chemicals or radiation
Smoking

Signs and symptoms of AML

The signs and symptoms of AML vary from person to person. They also depend on how many leukaemia cells you have, and how much your normal blood cell production has been affected.

Signs and symptoms include:

Feeling exhausted for no reason (fatigue)
Infections that last a long time or keep coming back
Feeling tired, breathless or dizzy due to a low red blood cell count (anaemia)
Bruising or bleeding easily (for example nosebleeds or bleeding gums when you brush your teeth)
A high temperature (fever)
Bone pain
Tummy pain, bloating or discomfort due to a swollen spleen or liver (you may particularly notice this feeling under your ribs on the left-hand side)
A feeling of fullness after eating, again due to a swollen spleen

Diagnosis of AML

Your haematology team will diagnose AML based on blood tests and bone marrow tests.

They will send your blood and bone marrow samples for specialised tests in the lab. Depending on your symptoms you might have further tests and scans.

It can be difficult waiting for test results. Our Helpline is here for you if you need support.

Blood tests

You will have blood tests to check the number of white blood cells, red blood cells and platelets in your blood.

If you have AML the blood test will usually show:

A low level of healthy white blood cells, red blood cells and platelets
A higher number of immature white blood cells

Bone marrow tests

You will usually also need a bone marrow test to help your haematology team make an accurate diagnosis.

The test involves taking a sample of your bone marrow, usually from the back of your pelvis, under local anaesthetic. They send the sample to the lab for testing.

Lab tests

Your team will send your samples for specialised tests in the lab.

They look at the samples under a microscope to check for abnormal cells.
They do tests to find out what proteins are on the surface of your cells.
They also do tests to look for genetic changes in your cells.

We have separate information about the genetic changes in AML.

Other tests

You might have an X-ray, ECG, CT scan or other scans to help work out which treatment options are best for you.

Depending on your symptoms, you may have a lumbar puncture to find out if there are any leukaemia cells in the fluid around your brain and spinal cord.

Outcomes of AML

As with most cancers, outcomes vary from person to person and depend on many different factors. These include:

Your age
Your AML subtype
The genetic changes in your leukaemia cells
Your overall fitness
Your blood cell counts
If you have any leukaemia cells left after treatment

Your haematology team are best placed to discuss what they expect for you because they know your individual circumstances.

Sources we used to develop this information

Ali S, Jones GL, Culligan DJ, Marsden PJ, Russell N, Embleton ND, Craddock C, British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol. 2015 Aug 1;170(4):487-95.

Dennis M, Copland M, Kaur H, Kell J, Nikolousis E, Mehta P, Palanicawandar R, Potter V, Raj K, Thomas I, Wilson A. Management of older patients with frailty and acute myeloid leukaemia: a British Society for Haematology good practice paper. British Journal of Haematology. 2022;199(2):205-21.

Desborough M, Estcourt LJ, Doree C, Trivella M, Hopewell S, Stanworth SJ, Murphy MF. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews. 2016(8).

Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 Nov 1;107(9):2099-107.

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, The Journal of the American Society of Hematology. 2010 Jan 21;115(3):453-74.

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, The Journal of the American Society of Hematology. 2022 Sep 22;140(12):1345-77.

Haematological Malignancy Research Network (HMRN). Statistics: Acute myeloid leukaemia. https://hmrn.org/statistics/ [Accessed Jul 2024].

Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, The Journal of the American Society of Hematology. 2021 Dec 30;138(26):2753-67.

Heuser M, Ofran Y, Boissel N, Mauri SB, Craddock C, Janssen J, Wierzbowska A, Buske C. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020 Jun 1;31(6):697-712.

Hickey M, Basu P, Sassarini J, Stegmann ME, Weiderpass E, Chilowa KN, Yip CH, Partridge AH, Brennan DJ. Managing menopause after cancer. The Lancet. 2024 Mar 9;403(10430):984-96.

Lachowiez CA, Long N, Saultz J, Gandhi A, Newell LF, Hayes-Lattin B, Maziarz RT, Leonard J, Bottomly D, McWeeney S, Dunlap J. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Advances. 2023 May 9;7(9):1899-909.

Loke J, Lowe DM, Miller LJ, Morton S, Roy NB, Sekhar M, Stanworth SJ. Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?. British Journal of Haematology. 2020 May 7.

Lustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology. 2023 Aug;20(8):527-42.

Mehta P, Telford N, Wragg C, Dillon R, Freeman S, Finnegan D, Hamblin A, Copland M, Knapper S. Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. British Journal of Haematology. 2023 Jan;200(2):150-9.

Pelcovits A, Niroula R. Acute myeloid leukemia: a review. Rhode Island medical journal. 2020 Apr 1;103(3):38-40.

Risi GF, Tomascak V. Prevention of infection in the immunocompromised host. American Journal of Infection Control. 1998 Dec 1;26(6):594-606.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-43.

Saraswat N, Chopra A, Sood A, Kamboj P, Kumar S. A descriptive study to analyze chemotherapy-induced hair loss and its psychosocial impact in adults: Our experience from a tertiary care hospital. Indian Dermatology Online Journal. 2019 Jul 1;10(4):426-30.

Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, LeBlanc TW. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Advances. 2020 Aug 11;4(15):3528-49.

Shirley MH, Sayeed S, Barnes I, Finlayson A, Ali R. Incidence of haematological malignancies by ethnic group in England, 2001–7. British Journal of Haematology. 2013 Nov;163(4):465-77.

Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D, Cardoso F. Central venous access in oncology: ESMO Clinical Practice Guidelines. Annals of Oncology. 2015 Sep 1;26:v152-68.

Stubbins RJ, Francis A, Kuchenbauer F, Sanford D. Management of acute myeloid leukemia: a review for general practitioners in oncology. Current Oncology. 2022 Aug 30;29(9):6245-59.

Todd WM. Acute myeloid leukemia and related conditions. Hematology/Oncology Clinics. 2002 Apr 1;16(2):301-19.

Vakiti A, Reynolds SB, Mewawalla P. Acute myeloid leukemia. In: StatPearls 2024 Apr 27. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK507875/ [Accessed Jul 2024]

Wong HM. Oral complications and management strategies for patients undergoing cancer therapy. The Scientific World Journal. 2014;2014(1):581795.

Need support?

You are not alone. We're here for you whether you have a diagnosis yourself or know someone who has. If you'd like advice, support, or a listening ear, call our freephone helpline on 08088 010 444 or send a WhatsApp message to 07500 068 065.

Talk to us

Help us improve our information

We aim to provide information that’s reliable, up-to-date, and covers what matters to you. Please complete our short survey to help us improve our information and make sure it meets your needs.

Complete our short survey

About our information

This information is aimed at people in the UK. We do our best to make sure it is accurate and up to date but it should not replace advice from your health professional. Find out more about our information.

Page last reviewed: 30 November 2024

Updated January 2026

Next review due: 30 November 2027

Need help understanding this information?

Our support team is here to answer your questions and provide guidance.

Contact Support

Find your type

Help line

Take on a challenge